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CLINICAL PRESENTATIONS, MANAGEMENT OPTIONS AND
OUTCOME IN CARCINOMA OF VULVA
ABSTRACT
OBJECTIVE: Carcinoma of the vulva is a relatively rare disease accounting for 0.3% of all
cancers affecting females and 1.3% of all gynecological malignancies in Chennai. Aim of the
present study is to analyze the clinical presentations, treatment options, morbidity, failure pattern
and survival for invasive carcinoma of vulva treated in our institution during a period of eight
years and to compare our results with other published series.
MATERIALS AND METHODS: Retrospective analysis of case records of 35 patients who
underwent surgery for invasive carcinoma of the vulva from 2004 to 2011 in the Department of
Surgical Oncology, Government Royapettah Hospital, Chennai.
RESULTS: The mean and median age was 52.5 years and 55 years respectively (range 21-72).
Labia majora was the predominant site of disease (80%). Twenty eight patients underwent
Radical Vulvectomy with Nodal Dissection, 2 underwent Hemivulvectomy with Nodal
Dissection, 2 underwent Simple Vulvectomy, 2 underwent Wide Local Excision and 1
underwent Wide Local Excision with Nodal Dissection. Lymphadenectomy was not done in 4
patients. With a median follow up of 26 months (range 2-67 months), 8 patients (22.9%)
developed recurrence, of which one is systemic, 4 regional and 3 local. The estimated 5 year
Overall Survival (OS) and Disease Free Survival (DFS) for all cases in our series using Kaplan-
Meier analysis was 85.1% and 65.4% respectively. On univariate analysis using log rank test,
advanced stage, lymph node positivity and lymph node positivity with extracapsular spread
(ECS) significantly affected estimated 5 year overall survival.
CONCLUSION: Carcinoma  vulva,  a  relatively  rare  disease  should  better  be  managed  in
dedicated cancer centers where treatment can be tailored to individual patients with
multidisciplinary cooperation. The median age in our series was 55 years which is well below the
western world. Extracapsular nodal spread was observed as the strongest prognostic factor for
survival in our series like other international series.  Since there has been a dearth of reports
about this disease from our country as well as other developing countries we urge the need for
more studies from various centers and probably well designed multicentric studies keeping in
mind the low prevalence of this disease.
Key Words: Carcinoma Vulva; morbidity; recurrence; survival.
INTRODUCTION
Carcinoma vulva is a relatively rare disease accounting for 4% of all
gynecological malignancies in United States1. It constitutes 0.3% of all cancers
affecting females and 1.3% of all gynecological malignancies in Chennai2. The
vulva is the anatomic area immediately external to the vagina. It includes the labia
and the perineum. The inguinofemoral nodes are the sites of regional spread.
Tumor involvement of pelvic lymph nodes is considered distant metastasis.
Cases should be classified as carcinoma of the vulva when the primary site
of the growth is in the vulva. Tumors present on the vulva as secondary growths
from extragenital site should be excluded. TNM stages are based on clinical and/or
pathological classification3. FIGO (Fédération Internationale de Gynécologie et
d’Obstétrique) uses surgical/pathologic staging for carcinoma of vulva4. Stage
should be assigned at the time of definitive surgical treatment or prior to radiation
or chemotherapy if either of these is the initial mode of therapy. The stage cannot
be changed on the basis of disease progression or recurrence or on the basis of
response to initial radiation or chemotherapy that precedes primary tumor
resection.
Carcinoma of the vulva mainly affects the elderly population, although it is
becoming increasingly common in younger women5. Most patients in developing
countries such as India present with advanced loco-regional disease for various
socio-economic reasons, including lack of awareness, resulting in poorer outcomes
and posing management challenges6. Most of our patients have hesitancy to have
examination of the external genitalia which may also be an important factor for
advanced disease at presentation.
Most of the literature on carcinoma of vulva is from the western world.
There is a striking paucity of literature related to this subject from the developing
countries. Due to the tumor rarity, large prospective randomized trials to guide
management are few in this disease. The purpose of this analysis is to know the
demographic pattern of invasive carcinoma of vulva in our patients, post operative
complications and outcome following surgery which will be of immense help in
the understanding of this relatively rare disease so as to plan continued evaluation
and future studies to improve our multimodal treatment option to reduce morbidity
without oncological compromise and also to compare our results with other
international series.
AIM OF THE STUDY
1. To study the various methods of clinical presentation
2. To study  management options
3. To analyze the outcome
MATERIALS AND METHODS
A retrospective analysis of all patients who underwent surgery for invasive
carcinoma of the vulva in our Department of Surgical Oncology, Government
Royapettah Hospital during a period of 8 years between 2004 and 2011 was carried
out. All patients were treated with curative intent, and followed up regularly. The
preoperative evaluation consisted of complete clinical examination including
detailed gynecological examination, routine blood and urine examination, chest
radiography, US (Ultrasonogram) abdomen and pelvis. CECT (Contrast Enhanced
Computed Tomography) abdomen and pelvis including the groin was done as
indicated. Selected patients were additionally evaluated with examination under
anesthesia (EUA) and Cystoscopy. Histopathological documentation of the
primary lesion was done for all cases preoperatively.
Of those 35 patients, 28 underwent Radical Vulvectomy (RV) with nodal
dissection, 2 underwent Hemivulvectomy with nodal dissection, 2 underwent
Simple Vulvectomy (SV), 2 underwent Wide Local Excision (WLE) alone and 1
underwent Wide Local Excision with nodal dissection.
In this series, except a few variations in surgical practice to assess the
lymphatic spread in the earlier periods, all patients were treated with same concept.
During RV, the primary lesion was removed with a minimum of 1 cm margin of
normal tissue in all directions with the incision extending down to the inferior
fascia of the urogenital diaphragm. Bilateral labia majora and minora including the
clitoris were included in the surgical specimen. Each inguinofemoral node
dissection was performed using separate incisions from the vulva incision.
Three patients received pre-operative EBRT (External Beam Radiation
Therapy - 50GY in 25 fractions) and one patient received pre operative concurrent
Chemo-RT using Cisplatin and 5-fluorouracil (5-FU) as chemotherapeutic agents.
All other patients underwent upfront surgery. After surgery, patients with margin
positivity, involvement of more than 1 node and presence of extracapsular disease
even in 1 node were given adjuvant EBRT.
Patients were followed up monthly in the first year, 2 monthly in the second
year, 3 monthly in the third year, 6 monthly for fourth and fifth years and yearly
thereafter. Follow-up included clinical examination at each visit, yearly chest x-ray
and, CECT abdomen with pelvis and other investigations as indicated.
The demographic pattern, clinical presentation, management options,
postoperative complications, failure pattern and survival were analyzed. Survival
analysis was done using Kaplan Meier method with SPSS 17? (SPSS Inc, USA)
for Windows Software. The log-rank test was used in the univariate analysis to
identify the potentially important prognostic variables. P-value of less than 0.05
was considered to be statistically significant. Results were compared with
published data available in the literature.
RESULTS AND ANALYSIS
Over this 8 year period, 35 patients with invasive carcinoma of the vulva
were treated with surgery in our Department. Preoperative radiation was given for
3 patients because of large inguinal nodal enlargement. One young patient received
preoperative chemoradiation because of extensive local disease with involvement
of distal urethra. In the remaining 31 patients, upfront surgery was done. Till date
no sentinel lymph node procedure was performed for carcinoma of the vulva in our
Department. Human Papilloma Virus (HPV) status was also not evaluated.
The mean age of the patients in our series was 52.5 years with a range of 23
– 73 years. The median age at presentation was 55 years. Of those 35 patients, 22
patients were less than 60 years (62.9%). Ten patients (28.6%) were less than 50
years (Table-1). Most of our patients were between 50 to70 years (25/35=71.4%).
TABLE 1
AGE GROUP
Age Group in years Frequency
20-29 2
30-39 2
40-49 6
50-59 12
60-69 12
70-79 1
Total 35
Almost all of our patients were referred from various centers. All of our
patients were symptomatic. Some patients presented with more than one symptom.
Thirty two (91.4%) of the patients presented with ulcer over external genitalia, 26
(74.3%) of the patients presented with pruritus vulvae, 8 patients (22.9%)
presented with pain and 6 (17.1%) patients presented with other complaints like
discharge,  swelling  (Table-2).
TABLE 2
CLINICAL PRESENTATION
Symptom Frequency Percentage (%)
Ulcer 32/35 91.4%
Pruritus 26/35 74.3%
Pain 8/35 22.9%
Others 6/35 17.1%
Labia majora was the predominant site of disease in 80% of our patients and labia
minora in 14.3%. Clitoris was the predominant site in 5.7% of the patients. Right
side of the vulva was predominantly affected in 60% of the patients and the left
side in 11.4%. In 28.6 % of the patients the disease was bilateral and hence
laterality cannot be fixed. The details of the site and side of involvement are given
below in table-3 &4.
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TABLE 3
PREDOMINANT SITE OF INVOLVEMENT
Site Frequency Percentage (%)
Labia Majora 28/35 80%
Labia Minora 5/35 14.3%
Clitoris 2/35 5.7%
TABLE 4
PREDOMINANT SIDE OF INVOLVEMENT
Side Frequency Percentage (%)
Right 21 60%
Left 4 11.4%
Bilateral 10 28.6%
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Of those 35 patients, 28 underwent Radical Vulvectomy (RV) with nodal
dissection, 2 underwent Hemivulvectomy with nodal dissection, 2 underwent
Simple Vulvectomy (SV), 2 underwent Wide Local Excision (WLE) alone and 1
underwent Wide Local Excision with nodal dissection.
In our center, Radical Vulvectomy was done using three separate incisions,
one for the radical vulvectomy and one for each groin dissection. Primary lesion
was removed with a minimum of 1 cm margin of normal tissue in all directions
with the incision extending down to the inferior fascia of the urogenital diaphragm.
Both labia majora and minora including the clitoris were included in the surgical
specimen. In Wide Local Excision, the primary lesion was excised with a
minimum of 1 cm margin of normal tissue in all directions, with the incision
extending down to the inferior fascia of the urogenital diaphragm, preserving the
other uninvolved part of vulva.
Unlike radical vulvectomy, Simple vulvectomy does not require an incision
all the way to the perineal fascia. The skin and subcutaneous tissues, labia majora,
labia minora and clitoris of the vulva are removed enbloc with the tumor.
Inguinofemoral block dissection was performed through a transverse
incision below the inguinal ligament, following the standard method without any
modification. After doing standard complete inguinofemoral block dissection,
sartorius transposition was done for all patients to protect the femoral vessels in the
event of subsequent wound breakdown. The practice of saphenous vein
preservation was not followed in our institution. In our institution, iliac nodal
dissection was not practiced from the year 2005. Before that period, iliac node
dissection was done if the inguinal nodes were positive by frozen section analysis.
The various surgical procedures performed were given below in table-5.
TABLE 5
SURGICAL TREATMENTS OFFERED
Surgical treatment Frequency Percentage (%)
Radical Vulvectomy with Nodal
Dissection
28/35 80%
Hemivulvectomy with Nodal
Dissection
2/35 5.7%
Simple Vulvectomy 2/35 5.7%
Wide Local Excision 2/35 5.7%
Wide Local Excision with Nodal
Dissection
1/35 2.9%
Generally in our institution, no reconstructive procedures were done for the
post vulvectomy area. In one of our patient, bilateral gracilis myocutaneous flap
was done for reconstruction of the primary area since the patient had removal of
Surgical Treatments Offered
Radical Vulvectomy with Nodal Dissection
Hemivulvectomy with Nodal Dissection
Simple Vulvectomy
Wide Local Excision
Wide Local Excision with Nodal Dissection
lower part of vagina for adequate clearance. In all other patients, wounds
were closed  primarily  without  any  flap (Table-6).
TABLE 6
TYPE OF RECONSTRUCTION FOR THE LOCAL AREA
Type of Reconstruction Frequency Percentage (%)
Flap (Bilateral Gracilis
Myocutaneous flap)
1/35 2.9%
Primary Closure 34/35 97.1%
In general, primary closure of the inguinal wound was done following
inguinofemoral block dissection in our center. However, depending upon the
clinical status of inguinal nodes and the need for sacrifice of skin, decision whether
to use flaps or primary closure was made. Of those 31 patients who underwent
nodal dissection, Tensor fascia lata myocutaneous flap (TFL flap) reconstruction
was done in 4 patients for whom primary closure alone was deemed to be
inappropriate. In all other patients, groin wound was closed primarily (table-7).
One of our patient needed tensor fascia lata myocutaneous flap (TFL flap)
reconstruction when ilioinguinal block dissection was done for regional recurrence
in the right inguinal region, 5months after simple vulvectomy.
TABLE 7
TYPE OF RECONSTRUCTION AFTER NODAL DISSECTION
Type of Reconstruction Frequency Percentage (%)
Flap (Tensor Fascia Lata
Myocutaneous Flap)
4/31 12.9%
Primary Closure 27/31 87.1%
Overall, in 4 of 35 patients, inguinal lymph node dissection was not
performed (Table-8). Of these, one patient (27 year old) who presented with
multiple verrucous lesions, who underwent simple vulvectomy alone, developed
nodal recurrence on right inguinal region 5 months after the primary surgery. She
was treated with right ilioinguinal block dissection with TFL flap reconstruction
followed by adjuvant RT because of the involvement of multiple nodes. After that
she was on follow-up for another 21 months and defaulted subsequent follow-up.
The remaining 3 patients had well lateralized disease with stromal invasion less
than 1 mm and hence node dissection was not done. These 3 patients are on regular
follow-up and they did not develop any recurrence till date. In two of our patients,
right inguinofemoral block dissection alone was done with right hemivulvectomy
without nodal dissection on opposite side for well lateralised lesion on labia majora
on the right side since the nodes were negative on frozen section examination.
Other than this, 4 cases underwent unilateral nodal block dissection.
TABLE 8
NODAL DISSECTIONS
Node Dissection No of Patients
Done During Primary Procedure 31
Not Done During Primary Procedure 4
Done for Nodal Recurrence 1
Post Operative Histopathology
Squamous Cell Carcinoma (SCC) is the most frequent form of cancer of the
vulva. All patients in our series were affected with SCC. Except 3 (2 had positive
margin, 1 had close margin), R0 resection was achieved in all patients (Table-9).
The nodes were found positive in 45.2% (14/31) of the patients those underwent
nodal dissection and negative in 54.8% (17/31) of the patients (Table-10). Of the
node negative patients, 3 developed recurrence (1 local, 1 regional, 1 systemic). Of
the node positive patients, 4 developed recurrence (2 local, 2 regional). Of the 4
patients who had nodal positivity with extra capsular spread, 3 died and 1 patient
NODAL DISSECTIONS
Done during Primary Procedure Not done during Primary Procedure
Done for Nodal recurrence
defaulted follow-up 14 months following surgery. The average node retrieval per
inguinofemoral block dissection in our series was 8.5 which remained well above
the recommended optimum number (6 nodes) 3.
TABLE 9
MARGIN STATUS FOLLOWING SURGERY
Margin
Status
Frequency Percentage
(%)
Adjuvant
Treatment
Recurrence
Negative 32 91.4% Depending upon
nodal status
8
Positive
and Close
Margin
3 8.6% 1st Patient? no
adjuvant treatment
(received Pre op.
RT)
2nd Patient? (1/4th
margin was
positive) defaulted
RT
3rd Patient?
(Close margin) no
adjuvant treatment
(received Pre op.
RT)
Nil
Nil
Nil
TABLE 10
NODAL STATUS FOLLOWING SURGERY
Nodal Status Frequency Percentage
(%)
Current Status
Node Positive with
ECS
4 11.4% 3 dead
1 defaulted follow-up
Node Positive
without  ECS
10 28.6% 1 dead
2 defaulted follow-up
1 alive with disease
6 alive
Node Negative 17 48.6% 1 defaulted follow-up
2 alive with disease
14 alive
Node Dissection
not done
4 11.4% 1 defaulted follow-up
3 alive
ECS  - Extra Capsular Spread
In our series, 36.4% of patients with clinically suspicious nodes had negative
findings at lymphadenectomy and 35% of patients with clinically negative nodes
had inguinal lymph node metastases (Table-11).
TABLE 11
CORRELATION OF CLINICAL FINDINGS WITH HISTOPATHOLOGY
Nodal Status Clinical Histopathology Both Clinical & HPE
Positive 11/31 14/31 7
Negative 20/31 17/31 13
Clinically positive, HPE positive?7
Clinically positive but HPE negative?4
Clinically negative but HPE positive?7
Clinically negative, HPE negative?13
Since 1988, the Federation International of Gynecologists and Obstetricians
(FIGO) have recommended the adoption of surgical-staging system in carcinoma
of vulva due to the clinical difficulties in diagnosing inguinal nodal metastasis.
After surgery our patients were fixed into various stages, according to FIGO-2009
Staging System4, 7 (Tables-12).
TABLE 12
DISTRIBUTION OF CASES ACCORDING TO FIGO STAGE (2009)
FIGO stage No of patients
I 18
II 2
III 13
IV 2
Post Operative Complications
No peri-operative mortality occurred in our series. Post operative
complications noted in our series were mainly due to nodal block dissection.
Majority of cases developed some amount of seroma after nodal block dissection.
Seroma requiring repeated aspirations was observed in 58.1% (18/31) of cases.
Skin flap necrosis (45.2 %) with wound gaping was the most worrisome
complication observed in our series following nodal dissection which increased the
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duration of hospital stay. The skin flap necrosis was salvaged with removal
of the necrosed part and secondary suturing in some cases and split skin graft after
making the wound to granulate well in few cases which caused delay in starting
adjuvant RT in indicated cases. We had necrosis of the pedicled flaps used for
reconstruction in 2 patients. In a 62 year old female following vulvectomy, the
primary wound was reconstructed with bilateral Gracilis myocutaneous flap who
already had received pre operative EBRT. She developed flap necrosis which
necessitated removal of flap on both sides. Post operatively patient had posterior
margin positivity and nodal involvement with extracapsular spread and she died
after 20 months. Another 48 year old female who received TFL flap for the
reconstruction of inguinal wound following nodal dissection, developed necrosis of
the distal part of the flap which was managed conservatively with removal of
necrosed part alone. She also developed deep venous thrombosis (DVT) in the
immediate post operative period which was managed successfully. Two patients
developed wound infection that was treated with appropriate antibiotics. The major
late complication was found to be lymphedema of legs which occurred in almost
all cases to certain extent but not producing significant problem. We did not
observe recurrent lymphangitis in any of the cases during follow-up. The post
operative complications occurred in our patients were given below in table-13.
TABLE 13
POST OPERATIVE COMPLICATIONS *
Complication Frequency Percentage (%)
Seroma requiring repeated
aspiration
18/31 58.1%
Necrosis of Skin Flaps
 Following Node Dissection
14/31 45.2%
Wound Infection 2/35 5.7%
Necrosis of Pedicled Flap
( TFL, Gracilis)
2 5.7%
Deep Venous Thrombosis 1 2.9%
*Some patients had more than one complication
Adjuvant Therapy
Adjuvant radiation therapy (EBRT) was given to patients with two or more
metastatic nodes, margin positive patients and for patients with extracapsular nodal
extension irrespective of number of nodes. Patients with negative lymph nodes,
clear resection margins and single node involvement without extracapsular spread
were followed expectantly with no adjuvant therapy. Twelve patients were
candidates for adjuvant RT, of which 5 defaulted therapy (Table-14). Of those 5
defaulters, two patients with nodal positivity remained disease free for 36, 41
months respectively and defaulted further follow up. One with margin positivity,
with negative nodes was found disease free till last follow up (67 months). One
with extracapsular nodal disease, developed regional recurrence and died in spite
of giving RT. One patient with retroviral positivity who underwent wide local
excision remained disease free till last follow up (39 months).
Table 14
Treatment Groups
Treatment Needed No of patients Percentage (%)
Surgery alone 19 54.3%
Surgery + Adjuvant RT 12 ( 5 defaulted) 34.3%
Preop RT/chemo-RT + Surgery 4 11.4
Pattern of Recurrence
At a median follow up of 26 months (range 2-67 months), 8 patients 22.9%
(8/35) developed recurrence, of which one is systemic, 4 regional and 3 local. Of
the 4 patients with regional recurrence, 2 developed nodal disease and the other
two developed soft tissue recurrence. Of the 2 with nodal disease, the patient who
had mobile node was treated with Right Ilioinguinal Block Dissection with TFL
(Tensor Fascia Lata) flap reconstruction followed by 50GY EBRT in 25 fractions
as adjuvant since she had multiple positive nodes. The other one who presented
with fixed nodal mass was treated initially with 50 GY EBRT and then another 16
GY EBRT because of poor response to initial therapy. She was put on
chemotherapy for residual disease. She received 1 cycle of chemotherapy with
Cisplatin and 5-Fluorouracil (CDDP & 5FU) and defaulted further therapy. Of the
two patients with soft tissue disease, one patient was a  defaulter of  adjuvant RT
and she developed ulcer left inguinal region 6 months after primary surgery and
was given  60 GY EBRT and finally succumbed to disease and  died  4 months
later. The other one developed soft tissue recurrence in right inguinal region 3
months after primary surgery and was salvaged with chemoradiation and she is on
regular follow up till date without disease.
 Of the 3 patients with local recurrence, 1 developed recurrence 33 months
after surgery.  She was planned for RT, but defaulted therapy. At the last follow-up
(13 months after the development of recurrence) she was alive with the disease.
One patient developed recurrence 21 months after primary surgery, and
chemotherapy was planned since she already received 50 GY EBRT as adjuvant
therapy. She received 1 cycle of chemotherapy with Cisplatin and 5-fluorouracil
(5-FU). Further chemotherapy was deferred because of poor general condition, and
she died after 4 months. The other one developed recurrence in the periurethral
region 21 months after primary surgery and defaulted therapy. In our series only
one patient developed systemic metastases involving lung and humerus and was
treated with local RT to bone and systemic chemotherapy with Cisplatin and 5-
fluorouracil (5-FU). Of these 8 patients, 3 were stage I, 4 were stage III, 1 was
stage II (FIGO-2009). The details of the pattern of recurrence are given below
(table-15).
Of the 8 patients, 5 developed recurrence within 1 year of surgery. One
patient developed recurrence within 2 year (21 months) and the other 2 patients
within 3 years (31, 33 months). An interesting observation that, all the regional and
systemic recurrences occurred within 1year of primary surgery in our series (4
regional and 1systemic). All 3 local recurrences occurred 1 year after primary
surgery (21, 31, 33 months). The exact reason for this observation was unknown.
Since the number of patients was low, any meaningful conclusion could not be
made.
TABLE 15
PATTERN OF RECURRENCE
Recurrence
Site
Time to
recurrence
(months)
Age
in
years
Lymph
node
status
Stage Adjuvant
treatment
Status
Regional 5 27 Not
known
I Nil Defaulted
follow-up
Regional 4 45 Positive
(single
node)
III Nil Dead
Local 33 55 Negative I Nil Alive with
disease
Local 31 48 Positive III RT Alive with
disease
Regional 6 50 Positive
with ECS
III Defaulted
RT
Dead
Local 21 54 Positive
with ECS
III RT Dead
Systemic 8 23 Negative II Nil Alive with
disease
Regional 3 45 Negative I Nil Alive
ECS – Extra Capsular Spread
Survival Analysis
Of those 35 patients, 4 (11.4%) died during follow-up and 5 (14.3%)
defaulted regular follow-up. Of the remaining 26 patients, 3 patients were alive
with disease and remaining 23 patients were on regular follow-up and were disease
free. The mean follow-up period for those 5 patients defaulted follow-up was 26
months (range 13 – 41 months). The estimated 5 year Overall Survival (OS) and
Disease Free Survival (DFS) for all cases in our series using Kaplan-Meier
analysis was 85.1% and 65.4% respectively. On univariate analysis using log rank
test, advanced stage, lymph node positivity and lymph node positivity with
extracapsular spread (ECS) have emerged as important prognostic factors that
significantly affected estimated 5 year overall survival. The important observation
was that the estimated 5 year OS for patients with nodal positivity with
extracapsular spread was significantly less than patients with nodal positivity
without extracapsular spread (P=0.015) and it was more significant when
compared with node negative patients (P=0.000). This highlights the importance of
extracapsular nodal spread as an important prognostic factor for survival. Since the
numbers of patients were low, multivariate analysis was not done.
At the same time, on univariate analysis using log rank test, advanced stage,
lymph node positivity did not affect the DFS to a statistically significant level. In
our series, the only factor that affected the DFS to a statistically significant level
was extracapsular nodal spread (Table-16). The DFS for patients with nodal
positivity without ECS (estimated 2 year DFS 63.5%, 3 year DFS 47.6%) was less
when compared to patients with node negativity (estimated 2 year DFS 87.1%, 3
year DFS 74.6%) but it was not significant (P=0.245). The DFS for patients with
nodal positivity with extracapsular spread was significantly less when compared
with patients with nodal positivity without extracapsular spread (P=0.023) and
patients with node negativity (P=0.011).
TABLE 16
DISEASE FREE SURVIVAL
Lymphnode Status Estimated 5 year DFS
Nodal Positivity with ECS 0%
Nodal Positivity without  ECS 66.7%
Node Negative 74.6%
Kaplan Meier Curve -Overall Survival for all Cases
Kaplan Meier Curve -Disease Free Survival for all Cases
REVIEW OF LITERATURE
Carcinoma of vulva is an uncommon disease affecting the elderly
population. Despite its infrequency, vulvar cancer remains an important female
disease, because of its significant impact on sexuality. Over the past decade,
numerous advances have been made in the management of vulvar cancer, with a
trend toward more conservative surgery. Early detection and biopsy of any
abnormal vulvar lesions are imperative to achieve diagnosis of vulvar cancer in the
early stages and to improve subsequent morbidity and survival.
Regarding anatomy8, the vulva includes the mons pubis, labia majora, labia
minora, clitoris, vestibule, vestibular bulb and the greater vestibular glands. The
arterial blood supply is derived from the superficial and deep external pudendal
branches of the femoral artery and the internal pudendal artery on each side.
Venous drainage of the vulval skin is via external pudendal veins to the long
saphenous vein. Venous drainage of the clitoris is via deep dorsal veins to the
internal pudendal vein and superficial dorsal veins to the external pudendal and
long saphenous veins.
The mons pubis is the rounded hair-bearing area of skin over the pubic
symphysis and adjacent pubic bone. It is formed by a mass of subcutaneous
adipose connective tissue. The labia majora are two prominent, longitudinal folds
of skin that extend back from the mons pubis to the perineum. They form the
lateral boundaries of the vulva. Each labium has an external, pigmented surface
covered with hairs and a smooth, pink internal surface with large sebaceous
follicles. The labia are thicker anteriorly, where they join to form the anterior
commissure. Posteriorly they do not join, but instead merge into neighbouring
skin, ending near and almost parallel to each other. The connecting skin between
them forms the posterior commissure that overlies the perineal body and is the
posterior limit of the vulva.
The labia minora are two small cutaneous folds, devoid of fat, that lie
between the labia majora. They extend from the clitoris obliquely down flanking
the vaginal orifice. Anteriorly, each labium minus bifurcates. The upper layer of
each side passes above the clitoris to form the prepuce, which overhangs the glans
of the clitoris. The lower layer of each side passes below the clitoris to form the
frenulum of the clitoris. The vestibule is the cavity that lies between the labia
minora. It contains the vaginal and external urethral orifices and the openings of
the two greater vestibular (Bartholin's) glands and of numerous lesser vestibular
glands.
The clitoris is an erectile structure partially enclosed by the anterior
bifurcated ends of the labia minora. It has a root, body and glans. The body can be
palpated through the skin. It contains two corpora cavernosa, composed of erectile
tissue and enclosed in dense fibrous tissue, and separated medially by an
incomplete fibrous pectiniform septum. The fibrous tissue forms a suspensory
ligament that is attached superiorly to the pubic symphysis. Each corpus
cavernosum is attached to its ischiopubic ramus by crus that extend from the root
of the clitoris. The glans clitoris is a small round tubercle of spongy erectile tissue
at the end of the body and connected to the bulbs of the vestibule by thin bands of
erectile tissue.
Perineal membrane (previously the inferior fascia of the urogenital
diaphragm) is a triangular membrane, attached laterally to the periosteum of the
ischiopubic rami and its apex is attached to the arcuate ligament of the pubis. The
posterior border is fused with the deep part of the perineal body and is continuous
with the fascia over the deep transverse perinei. It is crossed by the urethra, 2–3 cm
behind the inferior border of the symphysis pubis; the vagina, centrally; the ducts
of Bartholin's glands, posterolateral to the urethral orifice; the deep dorsal vessels
and dorsal nerves of the clitoris, behind the pubic arch in the midline; the posterior
labial vessels and nerves, anterior to the transverse perinei.
The femoral triangle is a depressed, intermuscular space in the anteromedial
aspect of the proximal thigh. The inguinal ligament constitutes the base of the
femoral triangle's inverted triangular outline. Its lateral boundary is the medial
margin of sartorius. Its medial boundary is the medial margin of adductor longus.
Its distal extremity, the apex, is where sartorius overlaps adductor longus. Its floor
is provided laterally by iliacus and psoas major, medially by pectineus and
adductor longus. Its roof is the overlying fascia lata. The femoral vessels, passing
from midbase to apex, are in the deepest part of the triangle. Lying lateral to the
artery and outside the femoral sheath is the femoral nerve, which, on entering the
femoral triangle divides into multiple branches. The triangle also contains fat and
lymph nodes.
The tensor fascia lata (TFL) originates from the anterior superior iliac spine.
It inserts into the fascia lata and is supplied by the lateral femoral circumflex
artery. It can be used as a myocutaneous flap for the reconstruction of inguinal
wounds following inguinofemoral lymphadenectomy where there is significant
skin loss. It is a Type-I flap based on a single vascular pedicle (ascending branch
of the lateral circumflex femoral artery). The flaps are easily made long enough to
reach and close the large area created during inguinofemoral lymphadenectomy in
few cases.
Gracilis myocutaneous flap is a Type-II flap based on dominant and minor
vascular pedicles. The gracilis flap can be harvested as either a muscle or
musculocutaneous flap. The dominant pedicle is the ascending branch of the
medial circumflex femoral artery. The minor pedicles are the first and second
branches of the superficial femoral artery. The muscle is innervated by the anterior
branch of the obturator nerve which enters it on its deep surface, superior to the
vascular pedicle. It can be used in the reconstruction of post vulvectomy area in
selected cases.
Regarding lymphatic drainage, a meshwork of connecting vessels join to
form three or four collecting trunks around the mons pubis which drain to
superficial inguinal nodes lying on the cribriform fascia covering the femoral
artery and vein; these nodes drain through the cribriform fascia to the deep inguinal
nodes lying medial to the femoral vein. The deep inguinal nodes drain via the
femoral canal to the pelvic nodes. The last of the deep inguinal nodes lies under the
inguinal ligament within the femoral canal and is often called Cloquet's node.
Lymph vessels from the clitoris and labia minora drain to deep inguinal nodes and
direct clitoral efferents may pass to the internal iliac node. Direct spread to the
deep nodal groups without metastasis to the superficial group has been documented
using lymphatic mapping. This type of direct spread is uncommon and represents
fewer than 5% of cases. Despite the extensive anastomosis of lymphatics,
metastasis of vulvar carcinoma to contralateral nodes is uncommon in patients with
well lateralized T1 lesions.
The vulvar lymphatics run anteriorly through the labia majora, turn laterally
at the mons pubis, and drain primarily into the superficial inguinal lymph nodes.
Elegant lymphatic dye studies by Parry-Jones9 demonstrated that vulvar lymphatic
channels do not extend lateral to the labiocrural folds and generally do not cross
the midline unless the site of dye injection is at the clitoris or perineal body.
Vulvar cancer spreads by the following routes:
? Direct extension, to involve adjacent structures such as the vagina, urethra,
and anus
? Lymphatic embolization to the regional inguinal and femoral lymph nodes
? Hematogenous spread to distant sites, including the lungs, liver, and bone
Haematogenous spread and spread by direct extension are both infrequent.
Two different pathways for Squamous Cell Carcinoma (SCC) of the vulva
have been put forth10. The first pathway is triggered by infection with a high-risk-
type Human Papilloma Virus (HPV). Integration of the HPV DNA into the host
genome leads to the development of a typical Vulvar Intraepithelial Neoplasia
(VIN), accompanied with over expression of p14ARF and p16INK4A. This lesion
subsequently forms a warty or basaloid type SCC. The second pathway is HPV-
independent where keratinizing SCC develops within a background of lichen
sclerosus (LS) through a differentiated VIN. It has a different set of genetic
alterations than those in the first pathway, including p53 mutations, Allelic
Imbalances (AI), and Microsatellite Instability (MSI). Characteristics of the warty /
basaloid type and the keratinizing type of SCC of the vulva are shown in Table –
17.
TABLE 17
TWO DIFFERENT TYPES OF VULVAR SCC
Variables Warty or Basaloid
type
Keratinizing type
Frequency 20%–35% 65%–80%
Age
Younger
55 (35–65) Years
Older
77 (55–85) Years
Precursor Warty or Basaloid VIN Lichen Sclerosus DifferentiatedVIN
Molecular
characteristics HPV Integration p53 Mutation
Prognosis Better Worse
About 70% of vulvar squamous carcinomas arise primarily on labia. Disease
more commonly occurs on the labia majora; however, it may appear on the labia
minora, clitoris and perineum. The disease is localized and well demarcated;
although it can occasionally be so extensive that the primary location cannot be
determined11.
More than 90% of invasive vulvar cancers are squamous cell carcinomas12.
The other histopathologic types are as follows:
? Bartholin's gland carcinoma
? Primary mammary adenocarcinoma
? Malignant melanoma
? Vulvar sarcoma
? Paget's disease
? Basal cell carcinoma
Diagnosis of vulvar carcinoma is often delayed. Women neglect to seek
treatment for a considerable period of time from the onset of symptoms11. In many
cases, a biopsy of the lesion is not performed until the problem fails to respond to
numerous topical therapies. A biopsy should be performed when any discrete
lesion of the vulva is discovered. The most common presentation is a pruritic
lesion of the vulva or a mass detected by the patient herself. However, early vulvar
cancer may be asymptomatic and recognized only with careful inspection of the
vulva. More advanced vulvar carcinomas present with bleeding, pain, or discharge.
During the past 20 years, a number of significant advances have been made
in the management of carcinoma of vulva, reflecting a paradigm shift towards a
more conservative surgical approach without compromised survival and with
markedly decreased physical and psychological morbidity. Great effort has been
devoted to decreasing the morbidity of surgery for vulvar carcinoma. They are as
follows13:
? Individualization of treatment for invasive carcinoma of vulva
? The use of separate incisions for lymphadenectomy to improve wound
healing
? Elimination of routine pelvic lymphadenectomy
? Omission of lymphadenectomy for patients with T1 tumors with  <1 mm
of stromal invasion
? Vulvar conservation for patients with unifocal tumors
? Omission of the contralateral groin dissection in patients with lateral T1
lesions and negative ipsilateral nodes
? The use of postoperative radiation therapy to decrease the incidence of
recurrence in patients with multiple positive groin nodes
? The use of preoperative radiation therapy in patients with advanced
disease
In the early part of the 20th century, patients commonly presented with
advanced disease, and surgical techniques were poorly developed; thus, the 5-year
survival rate for vulvar cancer was 20% to 25%. Taussig, in the United States, and
Way, in Great Britain, pioneered the radical en bloc dissection for vulvar cancer14,
15. Since the early part of the 20th century, the traditional surgery has been a
radical resection of the primary lesion with a bilateral groin node dissection
performed through a single incision. This operation involves radical removal of the
entire vulva, the mons pubis, the inguinofemoral lymph nodes, and often the pelvic
lymph nodes. A large surgical defect is created that is generally closed under
tension with a high subsequent breakdown rate and marked disfigurement of the
genital area.  Although this technique was later modified to remove less skin, the
primary wound breakdown rate exceeded 50%.
Fred Taussig collected a large series of vulvar cancer cases from 1911-
194014. He initially started his series with a radical excision of the primary tumor
with an en bloc dissection of the inguinal lymph nodes. Later, he modified his
technique for patients with small lesions in an attempt to decrease operative
morbidity. He used separate incisions for the groin dissection and the vulvar
excision. This less radical operation for small lesions was not routinely used until
Hacker reported his experience 198116. The report by Hacker and colleagues in
1981 consisted of 100 patients in whom three separate incisions were used to
perform the bilateral inguinofemoral lymphadenectomy and radical vulvectomy,
leaving a bridge of tissue between the incisions and sparing the mons pubis. Major
groin wound breakdown occurred in 14 patients, which was a considerable
reduction from the 50% or higher groin wound breakdown rate generally seen with
the en bloc excision.
Although a number of modifications have been described, the basic incisions
for radical vulvectomy and bilateral lymphadenectomy can be described as being
based on either a butterfly or longhorn approach17. The butterfly incisions use
convex wings over the groins and around the anus to facilitate closure of the
defect. The longhorn incisions were developed to limit skin resection over the
groin in an attempt to reduce wound breakdown.
BUTTERFLY INCISION FOR EN BLOC RADICAL RESECTION
MODIFIED SKIN-SPARING LONGHORN INCISION FOR EN BLOC
RADICAL RESECTION
Oncologically no significant difference was noted between radical excisions
of the primary tumor with an en bloc dissection of the inguinal lymph nodes
through single incision and triple incision with the advantage of reduced wound
morbidity in the triple incision method. After this observation, surgery for vulvar
carcinoma was done using triple incision technique. Then as a continuing trend
towards reducing the wound morbidity; radical wide local excisions of the vulvar
carcinomas were carried out sparing the uninvolved normal vulva without
oncological compromise.
THREE SEPARATE INCISIONS
Unilateral lesions (defined as 1cm or more from the midline) present another
variation for therapy11. Homesley et al in GOG study confirmed the low incidence
of contralateral node involvement, making ipsilateral inguinal lymphadenectomy a
rational initial approach18 .
UNILATERAL LYMPHADENECTOMY FOR A WELL-LATERALIZED
LESION
The following table 12(Table-18) shows an overview of five studies, which
registered the percentage of inguinofemoral lymph node metastases related to
depth of invasion ? 1mm in patients with T1  (? 2cm) tumors. In  all  the  five
studies, there was no lymphnode involvement when the stromal invasion was ?
1mm in patients with T1 (? 2cm) tumors. Hence it is obvious that
lymphadenectomy can be avoided for T1 tumors with stromal invasion ? 1mm.
Table 18
LYMPHNODE METASTASIS IN T1 TUMORS WITH STROMAL
INVASION ? 1mm
Study
Number of
Patients with
Stromal invasion
? 1mm
Number of Patients
with Positive Nodes
who had  Stromal
invasion ? 1mm
Percentage
Binder et al.19 7 0 0%
Ross and
Ehrmann20
17 0 0%
Hoffman
et al.21
24 0 0%
Hacker et al.22 34 0 0%
Andreasson
and Nyboe23
8 0 0%
[
The International Society for the Study of Vulvovaginal Diseases (ISSVD)
had proposed this pathologic definition of microinvasive carcinoma of vulva:
* SCC having diameter of 2cm or less (as measured in fresh state)
* Depth of invasion of 1mm or less (measured from the epithelial–stromal
junction of the adjacent most superficial dermal papilla to the deepest point
of invasion)
* No vascular space invasion
These lesions do not need inguinal lymphadenectomy of any type as stated
above.
EARLY LESION WITH LYMPHADENECTOMY OMITTED
Like the changing concepts for surgery for vulvar cancers, concept of nodal
dissection has also undergone several changes, ranging from radical removal of
ilioinguinal nodes via single incision to sentinel node biopsy which can avoid
nodal block dissection if sentinel node is negative, thus avoiding the potential
morbidity of lymph node block dissection. The concept relies on the presumption
that the sentinel lymph node is the initial site of metastatic disease and that the
histology of the sentinel lymph node reflects the histology of the rest of the lymph
nodes in the basin.
In 1979, the International Federation of Gynecology and Obstetrics (FIGO)
approved a clinical classification for invasive squamous cell carcinoma of the
vulva. That was based on an analysis of tumor (T) by size and location; node (N)
status by palpation; distant metastases (M) as assessed by general and pelvic
examination; evaluation of the bladder or rectum, or both; and radiologic
investigation. Most patients with invasive carcinoma of the vulva were treated
surgically, and it was recognized through a number of studies that there were
substantial discrepancies between the clinical assessment of the inguinal lymph
node status and the surgical pathologic findings. The prognostic importance of the
lymph node status is significant, yet the accuracy of the clinical assessment of the
lymph nodes is limited. Microscopic metastases may be present in nodes that are
not clinically suspicious, and suspicious nodes may be enlarged because of
inflammation only. When compared with surgical staging, the percentage of error
in clinical staging increases from 18% for stage I disease to 44% for stage IV
disease13.
These factors led the Cancer Committee of the International Federation of
Gynecology and Obstetrics (FIGO) in 1988 to introduce a surgical staging system
for vulvar cancer. That system was based on well-established surgical-pathologic
prognostic criteria. Hacker concluded that the term microinvasive vulvar cancer
should be reserved for tumors with a depth of invasion ? 1mm, because of the
negligible risk on lymph node metastases. In 1995, stage I was divided into A and
B based on a depth of invasion less or greater than 1 mm. Another revision was
made in the year 2009, giving consideration to the number of nodes involved and
extracapsular nodal involvement. Over the years the UICC (International Union for
Cancer Control), AJCC (American Joint Committee on Cancer), and FIGO have
modified their staging systems for gynecological cancers so that all 3 systems are
virtually identical. It is inevitable that changes will, of necessity; occur as more
data and information emerge regarding molecular markers and mechanisms, as will
a more precise understanding of the actual genetic factors and aberrations involved
in cancer etiology and pathogenesis. An increasing awareness of prognostic
scoring systems and the incentive to adopt them is already evident and will play a
major role in future classification systems. The recent FIGO (Table-19) and TNM
staging are given below.
TABLE 19
FIGO STAGING FOR CARCINOMA OF VULVA (2009)
Stage Description
I Tumor confined to the vulva
IA Lesions 2 cm or less in size, confined to the vulva or
perineum and with stromal invasion 1.0 mm or less *
IB Lesions more than 2 cm in size or any size with stromal
invasion more than 1.0 mm, confined to the vulva or
perineum
II Tumor of any size with extension to adjacent perineal
structures (lower 1/3 urethra,  lower 1/3 vagina, anus) with
negative nodes
III Tumor of any size with or without extension to adjacent
perineal structures (lower 1/3 urethra,  lower 1/3 vagina,
anus) with positive inguinofemoral nodes
IIIA 1-2 lymph node metastasis(es)  (<5 mm)
One lymph node metastasis 5 mm or greater
IIIB Three or more lymph node metastases  (<5 mm)
Two or more lymph node metastases 5 mm or greater
IIIC Lymph node metastasis with extracapsular spread
IVA Tumor of any size with extension to any of the following:
upper 2/3 of urethra, upper 2/3 vagina, bladder mucosa,
rectal mucosa, or fixed to pelvic bone
Fixed or ulcerated regional lymph node metastasis
IVB Distant metastasis (including pelvic lymph node metastasis)
* Note: The depth of invasion is defined as the measurement of the tumor from the
epithelial–stromal junction of the adjacent most superficial dermal papilla to the
deepest point of invasion.
TNM stages are based on clinical and/or pathological classification but the
FIGO stages are based on surgical staging3.
TNM Classification for Vulvar Cancer -7th Edition
T = Tumor
T1a- Tumor confined to vulva/perineum, ? 2cm in size, and depth of invasion ?
1mm
T1b- Tumor confined to vulva/perineum, > 2cm in size, or depth of invasion >
1mm
T2- Tumor extension to lower ? urethra, lower ? vagina or anus
T3- Tumor extension to upper ? urethra, upper ? vagina, bladder or rectal
mucosa, or fixed to    the pelvic bone
N = Nodes
N0- No lymph nodes involved
N1a- 1 – 2 inguinofemoral lymph node metastasis each < 5mm
N1b- 1 inguinofemoral lymph node metastasis ? 5mm
N2a - ? 3 inguinofemoral lymph node metastases each < 5mm
N2b- ? 2 inguinofemoral lymph node metastases ? 5mm
N2c- Inguinofemoral lymph node metastases with extracapsular spread
N3- Fixed or ulcerated inguinofemoral lymph nodes
M = Metastasis
M0- No distant metastases
M1- Any distant metastases
Radiation therapy, frequently with concurrent chemotherapy, is gaining an
increasingly important role in the management of patients with vulvar cancer. The
indications for radiation therapy for patients with primary vulvar cancer are still
evolving. At present, radiation seems to be clearly indicated in the following
situations13:
? Preoperatively, in patients with advanced disease who would otherwise
require pelvic exenteration  or suffer loss of anal or urethral sphincteric
function
? Postoperatively, to treat the pelvic lymph nodes and groin of patients
with two or more microscopically positive or one grossly positive groin
node with extracapsular spread
?  Postoperatively, to help prevent local recurrences in patients with
involved or close surgical margins
Unfortunately, reports of chemotherapy activity in the treatment of
metastatic or recurrent squamous cell carcinoma of the vulva are largely anecdotal.
In the absence of reliable data specific to this cancer, clinicians often use single
agents and combination regimens that have had some activity in the treatment of
cervical cancer.
DISCUSSION
The mean age of the patients in our series was 52.5 years and the median age
was 55 years with a range of 23 to 73 years (2004-2011). In the 2 Indian series,
Bafna et al. (1996-2000) reported that the mean age of the patients was 54.7 years
with a range of 24 to 75 years and Sharma et al. (1998-2005) reported that the
median age was 63 years with the range of 24 to 92 years6, 24. In a study from
Nigeria (1998-2009), the ages ranged from 54 to 79 years with a mean of 61.2
years25.  In Landrum et al. (1990-2005) series the median age of 175 patients at the
time of primary diagnosis was 59.9 years with a range of 32 to 95 years26.  In  a
study by Hampl et al. the mean age was 57 years in their most recent cohort of 102
women (05/1998 to 06/2007), of those, 41.2% (42 women) were aged 50 years or
less and the youngest woman diagnosed with an invasive vulvar carcinoma was 18
years old with a history of sexual contact for three years and severe pain and
dysuria for several months5. In our series 45.7% (16/35) of the patients were aged
50 years and below and the youngest patient diagnosed was 23 years old. In Bafna
et al. series, 16 were less than 60 years (43.2%) 6.  When compared to western
patients the median age in our series is low (Table-20).
Table 20
THE MEAN AND MEDIAN AGE OF PATIENTS IN VARIOUS SERIES
Series Study
Period
Total
Patients
Mean Age
in Years
Median Age
in Years
Age Range
in Years
Bafna et al6 1996-
2000
37 54.7 60 24-80
Landrum et
al26
1990-
2005
175 - 59.9 32-95
Sharma et
al24
1998-
2005
60 - 63 24-92
Hampl et
al27
2003-
2006
127 61.4 - -
Hampl et
al5
1998-
2007
102 57 - 18-93
Eke et al25 1998-
2009
11 61.2 - 54-79
Present
Series
2004-
2011
35 52.5 55 23-73
Labia majora was the common site of primary lesion in our series
(28/35=80%). Hampl et al. in their series of 224 patients with vulvar cancers
reported that the tumor localization changed significantly from the labia to the area
between the clitoris and urethra5. They state that area between clitoris and urethra
seems to be the most frequent tumor site (38.4%). They further state that the
remarkable change of the tumor localization could be explained by the “higher
susceptibility of the non-keratinizing epithelium to tiny injuries or tears facilitating
HPV infection, the earlier onset of sexual non-penetrating contact in young
adolescents nowadays, promiscuity and/or a more rapid progression from infection
to VIN to invasive tumors without understanding how this occurs”. In our series
with low number of cases, such a shift in location was not observed and labia
majora was the common site of involvement. In our series, 14.3% (5/35) of disease
occurred in labia minora and 5.7% (2/35) of the disease occurred in clitoris.
HPV infection is now a well established cause of cervical cancer and there is
growing evidence of HPV being a relevant factor in other anogenital cancers (anus,
vulva, vagina and penis) and head and neck cancers. HPV types 16 and 18 are
responsible for about 70% of all cervical cancer cases worldwide28.  Since  HPV
testing was not done in our series, the status of HPV in our patients could not be
commented.
In  a  study  by  Shukla  et  al 29the following points were noted about the
prevalence of HPV infection in cancers of female genital organ. In India, 85-90%
cervical cancer cases are squamous cell carcinoma and the HPV 16 is the most
prevalent  type  among  them  compared  to  other  parts  of  the  world  where  the
proportion of HPV16 is much lower and ranges only upto 70% when both HPV16
and 18 are considered. In India, HPV type 16 alone in cervical cancer is 70-90%
while occurrence of HPV type 18 varies from 3 to 20%. Other highrisk HPV types
such as HPV 45, 33, 35, 52, 58, 59, and73 have also been reported are rare and
constitute only a minor group. Interestingly, the peak of HPV infection,
particularly HPV 16, appears to reach at later stage in third decade of sexual life at
26-35 years in Indian women in contrast to 18-25 years reported in western
countries. Etiologically vulvar carcinomas are heterogeneous and thus the presence
of HPV infection in invasive vulvar cancer cases varies. In India, no report is
available on the prevalence and type distribution of HPV infection in vulvar
cancer.
A  report  by  Dhir  et  al.30 provides the risk estimates for cancers in HIV-
infected (Human Immunodeficiency Virus) persons in India. These authors
examined HIV prevalence in persons with all types of cancer who presented at the
Tata Memorial Hospital, one of the largest tertiary cancer referral medical centers
in India, during 2001–2005. They used proportional incidence ratios (PIR) to
assess the likelihood that specific cancer types were associated with HIV infection,
comparing the cancer distribution in PHA to that in the age- and sex-specific
distribution of all cancer patients seen at the same medical center in 2002. HIV
infection was found in 1.2% of cancer admissions, including 166 men and 85
women. In women, Non Hodgkin Lymphoma (NHL) was increased 10-fold (n =
14), while one case of Hodgkin Lymphoma (HL) was observed (non-significant 2-
fold increase). Cervical (n = 33) and vulva/vaginal cancer (n = 2) risks were both
increased (4-fold and 8-fold, respectively). This report provided no data about
possible risk factors such as sexual practices, smoking or chewing tobacco, or
infections. In our series one patient was found to be positive for HIV. She
underwent wide local excision for cancer vulva and was advised adjuvant EBRT,
but defaulted. During the last follow-up (39 months) she remained disease free.
In the era of multimodality approach and organ conservation in the treatment
of cancer, the radicalism of surgery was gradually getting decreased over a period
of time. The traditional operative approach of radical en bloc resection of the vulva
and inguinofemoral nodes through single incision underwent a drastic change after
the landmark study by Hacker et al. They demonstrated that a less morbid surgical
approach, operating through separate vulvar and groin incisions, achieved cure
rates similar to those achieved with the traditional radical vulvectomy16. Since
then, there has been a continuing trend towards less radical surgery. For all our
cases requiring nodal dissection, separate incisions were used. Significant
reduction of wound complications and very low chance of recurrence in the tissue
bridge between the incisions were noted in international series16, 31. We follow the
same principle and we did not come across any recurrence in the tissue bridge
between the incisions.
Studying the relationship between surgical margins and tumor recurrence,
Heaps et al. reported no local failures in 91 patients whose closest tumor margin
was 8 mm or more in the fixed specimen32. As per the seminal article by Heaps et
al we routinely follow the practice of giving 1 cm gross margin to vulvar cancer. In
our series, except 3 (2 had positive margin, 1 had close margin), R0 resection was
achieved in all patients. Of these 3 patients, 2 had locally advanced disease for
which preoperative EBRT was given. The other one was treated with upfront
surgery.
Like treatment for the primary in carcinoma vulva, the radicalism of doing
pelvic lymphadenectomy along with inguinofemoral block dissection was
questioned after a landmark study by Homesley et al. In 1986, Homesley et al.33
published results of a prospective randomized study that compared pelvic
lymphadenectomy with inguinal and pelvic irradiation in patients with inguinal
node metastases from carcinoma of the vulva. All patients were initially treated
with radical vulvectomy and inguinofemoral lymphadenectomy. Patient
randomization was done intraoperatively after frozen-section evaluation of the
inguinofemoral lymph nodes. This trial was closed prematurely, after 114 eligible
patients had been entered, when interim analysis revealed a survival advantage for
the radiotherapy arm (P = .03). The difference was most marked for patients with
clinically positive or multiple positive groin nodes on histopathological
examination. For patients with two or more positive nodes, the 2-year survival
rates were 63% and 37% for the radiotherapy and pelvic lymphadenectomy groups,
respectively. With the publication of this study, most practitioners abandoned
routine pelvic lymphadenectomy, and postoperative radiotherapy became the
standard for most patients with inguinal node metastases.
Adjuvant radiation therapy was given to patients with two or more
metastatic nodes, margin positivity and extracapsular nodal extension irrespective
of number of nodes33. Patients with negative inguinal nodes and clear resection
margins were followed expectantly with no adjuvant therapy. We follow this
principle.
In Bafna et al. series, the nodes were negative in 13/26 (50%) cases who had
had groin lymph node dissection and all the patients with negative nodes have had
no evidence of disease  until their last follow-up6.  In  a  series  by Homesley et  al.
they reported that 24% of patients with clinically negative nodes had inguinal
lymph node metastases and 24% of patients with suspicious but mobile nodes had
negative findings at lymphadenectomy suggesting that the clinical examination is
inadequate in assessing the nodal spread18. For this reason, in 1988, the FIGO
staging system was changed from a clinical staging system to one that incorporate
the more accurate information gained from surgical assessment of regional lymph
nodes. In our series also, 36.4% of patients with clinically suspicious nodes had
negative findings at lymphadenectomy and 35% of patients with clinically negative
nodes had inguinal lymph node metastases post surgery, which is in concordance
with his view (Table-21).
TABLE 21
CLINICAL AND PATHOLOGICAL CORRELATION OF INGUINAL
NODES
Series Inguinal nodes - clinically suspicious,
negative finding at lymphadenectomy
Inguinalnodes - clinically
negative, positive finding
at lymphadenectomy
Homesley
et al18
24% 24%
Present
series
36.4% 35%
In a series by Le et al. the total number of nodes harvested during primary
surgical management was proved to be an independent predictor of both
progression- free and overall survivals. It is conceivable that the more nodes that
are removed, the less chance there is of missing an occult nodal metastasis, which
could affect timely treatment, thereby reducing recurrence. They propose to define
optimal inguinal nodal dissection using a cut-off value of at least 10 nodes in total
for patients undergoing bilateral inguinofemoral lymphadenectomy34. In our series
the nodal yield per bilateral inguinofemoral lymphadenectomy was 17 which
indicate optimal dissection.
Over the years, there has been a consistent trend toward less radicalism in
the operative management of invasive squamous cell carcinoma of the vulva.
Inguinal nodal dissections can be complicated by significant postoperative
complications such as infections, seroma, wound breakdown, as well as chronic
lymphedema of the extremities that seriously interfere with the quality of life of the
patients. To limit the morbidities associated with this procedure, some authors have
recommended either the use of sentinel node sampling or superficial nodal
dissection with saphenous vein preservation. Recently, a number of investigators
have explored the use of intraoperative lymphatic mapping to identify a sentinel
node that would predict the presence or absence of regional metastases27. Patients
without malignant deposit in sentinel node can be avoided from definitive nodal
dissection thus avoiding the potential complications of lymphadenectomy.
Currently, due to the lack of established long-term oncologic outcomes as well as
experience with sentinel node procedures in most centers, this approach remains
experimental. None of our patient with invasive carcinoma of vulva underwent
sentinel node biopsy.
Participants in a 2008 expert panel at an International Sentinel Node Society
Meeting concluded that sentinel node biopsy “is a reasonable alternative to
complete inguinal lymphadenectomy when performed by a skilled
multidisciplinary team in well selected patients”35. They concluded that patients
who have tumors that fulfill the following criteria are good candidates for the
procedure.
1. Tumors that invade more than 1 mm
2.  No obvious metastatic disease
3. Tumor diameter of less than 4 cm
Some surgeons have tried to reduce the incidence and severity of surgical
complications by reducing the extent of lymph node dissections. In April 1992, the
Gynecologic Oncology Group (GOG) reported the results of protocol 7436. A total
of 121 patients with negative superficial inguinal lymph nodes were observed, and
nine (7.3%) had a groin relapse. This relapse rate was compared with the long-term
follow-up of 81 control patients treated with complete inguinofemoral
lymphadenectomy on GOG protocol 36. Among the historical controls, there were
no groin relapses. The GOG properly rejected superficial inguinal
lymphadenectomy, and most gynecologic oncologists resumed performing
inguinofemoral lymphadenectomy. In 1995, Burke et al.37 reported 4 (5%) groin
recurrences in 74 patients with T1 or T2 tumors treated with wide local excision
and superficial inguinal lymphadenectomy (unilateral or bilateral depending on the
location of the tumor). However, a recent update of the M. D. Anderson Cancer
Center experience had longer follow-up and demonstrated a higher recurrence risk
of 16% at 5 years in patients treated with superficial lymphadenectomy alone38. It
has been suggested that the procedure used in these studies did not remove medial
inguinofemoral nodes that may be the primary site of drainage of some vulvar
cancers39; for this reason, many gynecologic oncologists now recommend removal
of at least the superficial and medial inguinofemoral nodes. Thus superficial
inguinal lymphadenectomy alone is not recommended at present. We follow
standard inguinofemoral lymphadenectomy for carcinoma of vulva.
In our series 45.2 %( 14/31) of patients develop skin flap necrosis (Table-
22). In Bafna et al. series, only three of 26 patients who had groin node dissection
had wound healing with primary intention, remaining 23 patients (88.4%) had
considerable groin wound dehiscence6. Zhang et al. published their retrospective
analysis comparing saphenous vein sparing to saphenous vein ligation during the
inguinal lymphadenectomy and its impact on the development of complications40.
They found significant decrease in the development of short-term lower limb
phlebitis in the saphenous vein spared group; otherwise, no significant differences
were noted between the two groups as regards the development of post-operative
wound seroma, acute inguinal wound cellulitis, or lymphocyst formation.
However, in a series by Soliman et al, they conclude that “local complications after
inguinofemoral  lymphadenectomy are still very high, with no single pre-, intra-, or
postoperative factor that could be incriminated, and saphenous vein sparing
provided no significant difference in decreasing the rate of local complications”41.
They suggested that more trials should be done to study the efficacy sentinel lymph
node detection technique in vulvar cancers so that the morbidity of inguinofemoral
block dissection can be avoided in sentinel node negative patients. In our
institution the practice of saphenous vein sparing was not done.
The sartorius muscle historically was transferred to the inguinal ligament to
cover the exposed femoral vessels. Judson et al reported this technique is not
beneficial based on a randomized control trial and it increased the risk of
lymphocyst formation42.  However we routinely practice this technique because, in
situations where inguinal wound gaping occurs due to skin flap necrosis this will
prevent exposure of major vessels.
TABLE 22
COMPARISON BETWEEN WOUND COMPLICATIONS
Series Wound
breakdown
Wound seroma Wound
infection
Gaarenstroom  et al.43 11% 27% 27%
Gould et al.44 19.4% 13.1% -
Soliman et al41 9.7% 12.5% 3.2%
Bafna et al6 88.4% - -
Present Series 45.2% 58.1% 5.7%
In our series, 5 (14.3%) patients defaulted follow up. However poor follow-
up in Indian females due to several factors like long travelling distance, poor socio
economic status and elderly age is not unusual24. Patients were kept on surveillance
at monthly interval for one year and two monthly interval for next year, three
monthly interval for next year and then six monthly for the next two years and
annually thereafter until the lifespan. During the follow up, if recurrent disease was
detected, patients were treated accordingly. However, in public sector hospitals
like ours, despite providing free transportation train pass and other facilities, due to
financial constraints, some of the patient dropout on follow-up. In a regional
cancer center in South India, they report that more than 50% were compliant to
treatment protocol, less than 30% default during adjuvant therapy and 20% default
after the preliminary investigation45.
At a median follow up of 26 months (range 2-67 months), 8 patients 22.9%
(8/35) developed recurrence, of which one is systemic, 4 regional and 3 local. This
failure pattern was almost like other reported series worldwide (Table-23). All the
regional and systemic recurrences occurred within 1year of primary surgery in our
series.
In a study by Woelber and colleagues46, in multivariate analysis, lymph node
status and age were the only independent prognostic factors for disease-free and
overall survival. After adjusting the level of significance to 0.02%, only nodal
involvement persisted as an independent prognostic factor (p=0.002). They state
that, the risk for recurrent disease was 5.1 times higher for patients with unilateral
lymph node involvement and 16.9 times higher for those with bilateral lymph node
involvement compared to those with negative nodes.
Studying the relationship between surgical margins and tumor recurrence,
Heaps et al. reported no local failures in 91 patients whose closest tumor margin
(deep  or  at  the  skin  surface)  was  8  mm  or  more  in  the  fixed  specimen32.
Accounting for specimen preparation and fixation, they suggested that 1-cm tumor-
free surgical margin on the vulva results in a high rate of local control, whereas a
margin <8 mm is associated with a 50% chance of recurrence. From that study 1cm
surgical margin was followed by most of the surgeons worldwide.
In a study by Groenen et al47, 93 patients underwent surgery for invasive
SCC of the vulva from 2000 to 2005. With a median follow-up of 31 months
(range, 2-90 months), 18 patients (23%) developed a local recurrence. The
recurrence rate did not differ between patients in whom the margin was 8 mm or
more and those in whom the margin was less than 8 mm, (23% and 22%,
respectively). There is discordance between his observation with that of Heaps et
al.
TABLE 23
FAILURE PATTERN IN FEW SERIES
Series Recurrence in
Percentage
Study
Period
Median
Follow-up In
months
Heaps et al32 15.6% (21/135) 1957-1985 -
Fonseca-Moutiho
et al48
26.8% (15/56) 1987-1997 -
Bafna et al6 32.4% (12/37) 1996-2000 -
Cheng et al49 34% (34/100) 1980-2002 -
Woelber et al 46 13.6% (14/103) 1996-2003 36
Le et al34 29.3% (17/48) 1980-2004 37
Landrum et al26 13% (22/175) 1990-2005 54.5
Sharma et al24 43% (26/60) 1998-2005 23
Groenen et al47 23% (18/93) 2000-2005 31
Present Series 22.9% (8/35) 2004-2011 26
In  a  study  by  Oonk  et  al50, 65 of 238 patients (27%) developed recurrent
disease within a mean of 25 months (median, 21 months; range, 3 – 76 months)
after the end of the primary treatment. Local recurrences occurred after a mean
progression-free survival of 30 months (median, 27 months; range, 4 – 76 months)
whereas regional recurrences (skin bridge and inguinal region) developed after 8
months (median, 8 months; range, 3 – 15 months) and distant recurrences after 11
months (median, 11 months; range, 4 – 22 months). The time between primary
treatment and recurrence was found to be longer for patients with local recurrences
compared with those with regional and distant recurrences (P=0.0001). Stehman et
al51 noted that groin recurrences occur sooner (median time to recurrence 6
months) than vulvar recurrences (median time to recurrence 3 years). In our series
also all the regional and systemic recurrences occurred within 1year of primary
surgery (4 regional and 1systemic) and all three local recurrences occurred 1 year
after primary surgery (21, 31, 33 months) which is in concordance with the above
reported series.
The estimated 5 year Disease Free Survival (DFS) and Overall Survival
(OS) in our series was 65.4% and 85.1% respectively. The 5-year overall survival
was 75.9% in a series from Singapore with a mean follow-up of 39 months52. In
the series from AIIMS (All India Institute of Medical Sciences) India, Sharma et
al. reported 41% five year survival for all stages24. In 1991, the GOG (Gynecologic
Oncology Group) reported the survival analysis of 588 patients and observed that
5-year survival in Stage I, II, III, and IV was 98, 85, 74 and 31% respectively 53.
This concludes stage as important prognostic marker. It also found out significant
correlation between number of positive nodes and survival. In our series, on
univariate analysis using log rank test, advanced stage, lymph node positivity and
nodal positivity with extracapsular spread significantly affected estimated 5 year
overall survival. Because of the changes in FIGO staging system over a period of
time, stage by stage comparison of survival between our series with other
international series may not be representative. But the outcome of our patients was
comparable with other reported series (Table-24).
TABLE 24
SURVIVAL IN CERTAIN SERIES
Series Disease FreeSurvival (DFS)
5 Year Overall
Survival (OS)
Sharma et al24 - 41%
Cheng et al49 66.5% -
Shamini et al52 - 75.9%
Present Series 65.4% 85.1%
About the 2 series from India, the one from South India concludes that ‘‘no
firm conclusions could be drawn given small number of patients, however it
appears from the present study that bilateral involvement of the inguinal lymph
nodes would carry a worse prognosis than unilateral involvement, provided
multiple nodes are not involved and  neoadjuvant chemotherapy appears beneficial
in selective locally advanced cases and the role of neoadjuvant chemotherapy
compared to neoadjuvant radiotherapy/ chemoradiation in locally advanced tumors
needs to be explored”6. In the other Indian series by Sharma et al. despite the
majority of patients presenting in advanced stage, the 5 year overall survival was
41%.They found that FIGO stage and pathological node positivity were the two
statistically significant prognostic factors for survival24.
In a retrospective analysis of 389 cases of vulvar cancer, Raspagliesi et al.
identified nodal status as the most significant prognostic factor among all tumor-
related variables and proposed that certain variables related to positive nodes (such
as extracapsular spread) could be critical for further risk assessment54. In contrast
to these results, a retrospective population-based study by Rhodes et al.
demonstrated an unfavorable survival for patients with positive inguinal lymph
nodes only in univariate analysis; after multivariate analysis, it did not retain its
prognostic significance55. These inconsistent findings are most likely caused by
heterogeneous treatment strategies in the investigated population, as Rhodes et al.
also observed that the management of vulvar cancer varied widely between
different centres, many of which treated only very few patients per year.
In a study by Landrum et al. the overall survival (OS) and progression free
survival (PFS) in patients with advanced vulvar cancer managed by either primary
surgery or primary chemoradiation  did not show any statistical difference between
these two groups. Interestingly, in that study, lymph node status was not a
predictor for OS or PFS and they proposed that “complete surgical excision of
inguinofemoral lymph nodes followed by adjuvant radiation resulted in improved
PFS and OS compared to that of historic controls and reduced the predictive value
of lymph node metastasis in that population”56.
In our series nodal positivity with extracapsular spread was the only factor
which significantly affected the estimated 5 year DFS. In 1995, van der Velden et
al.57 published a detailed study of nodal prognostic factors in 71 patients with
inguinal node metastases from vulvar carcinomas. Patients with extranodal spread
or more than two positive nodes received adjuvant radiotherapy to an unspecified
dose. The most powerful predictor of outcome in their study was extranodal tumor
extension: 28 of 44 patients (64%) with extranodal tumor died of disease versus 3
of 22 patients (14%) without this finding. Origoni et al.58 reported similar findings
in a series of 53 patients with positive nodes. In our study also lymph node
involvement with extracapsular spread was observed as a significant prognostic
factor for OS and DFS. Of the 4 patients with extracapsular nodal involvement, 3
died and 1 defaulted follow-up after 14 months.
Studies also suggest that, when corrected for the number of involved nodes,
lymph node bilateralism and local factors such as tumor size and early involvement
of adjacent structures have little impact on survival7. However, extracapsular nodal
extension was found to be a powerful prognostic indicator. In 2009, to incorporate
these findings and to improve the prognostic accuracy of FIGO staging system,
another major revision was implemented (extracapsular nodal spread is now FIGO
Stage IIIC) 7.
A possible limitation of our study is its retrospective and monocentric
nature, but the low prevalence of vulvar cancer makes prospective studies difficult
to complete. However, the decent number of patients with vulvar cancer treated in
our dedicated cancer center and the uniform treatment by a highly specialized
surgical team might be strengths of this study, as inter-patient variability in the
treatment regimens are very low.
CONCLUSION
Carcinoma vulva, a relatively rare disease should better be managed in
dedicated cancer centers where treatment can be tailored to individual patients with
multidisciplinary cooperation. The median age in our series was 55 years which is
well below the western world. On univariate analysis using log rank test, advanced
stage, lymph node positivity and lymph node positivity with extracapsular spread
(ECS) have emerged as important prognostic factors that significantly affected
estimated 5 year overall survival. Extracapsular nodal spread was observed as the
only prognostic factor that significantly affected both OS and DFS on univariate
analysis in our series.  HPV status of all vulvar cancers should be evaluated which
may help to study the association of the virus with this disease and the possibility
of potential prevention using vaccines.
Analyzing the epidemiological pattern, management options and outcome of
these patients will pave way for the future treatment protocols, proper
understanding of this disease and in the design of well controlled clinical trials
regarding management of this reatively rare disease with the aim of reducing the
morbidity without oncological compromise.
Since there has been a dearth of reports about this disease from our country
as well as other developing countries we urge the need for more studies from
various centers and probably well designed multicentric studies keeping in mind
the low prevalence of this disease. Uniform consensus should be arrived from
those well controlled studies regarding organ conservation strategies and morbidity
reducing approaches in nodal dissections.
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CLINICAL PHOTOGRAPH – CARCINOMA VULVA
STEPS OF RADICAL VULVECTOMY - 1
STEPS OF RADICAL VULVECTOMY - 2
SARTORIUS TRANSPOSITION
RADICAL VULVECTOMY –
SPECIMEN PHOTOGRAPH
POST OPERATIVE COMPLICATION –
FLAP NECROSIS
RADICAL VULVECTOMY - FOLLOW-UP
HEMIVULVECTOMY - FOLLOW-UP
 PROFORMA
Name:                                               Age:                Address:
Occupation:                                      Cancer Department No:
Chief complaints:
1. Itching
2. Ulcer
3. Pain
4. Others
H/o Present illness:
H/o Past illness:
H/o Co-morbid illness:
H/o Previous Treatment:
Previous H/o Malignancy:
Personal History:
 Family History:
Menstrual History:
General Examination:
Clinical Examination: Abdomen and Pelvis
PR & PV Examination
Thorough Gynecological Examination:
Examination of the Lesion:
1. Site
2. Predominant side
3. Size
4. Extent
1. Involvement of Vagina
2. Involvement of Urethra
3. Involvement of Anus
5. Nodal Status
Examination of other systems:
Investigations: Confirmation of disease, Routine Investigations, Metastatic Evaluation
1. Biopsy
2. Blood Investigations
3. Chest Radiography
4. Ultrasonogram Abdomen & Pelvis
5. Others (if necessary)
Preoperative Treatment:
1. Nil
2. Pre operative EBRT
3. Pre operative Chemo-RT
Treatment: Surgery
Type of Surgery
1. Simple Vulvectomy
2. Radical Vulvectomy
3. Hemivulvectomy
4. Wide Local Excision
Nodal Block Dissection
1. Side
a. Right
b. Left
c. Bilateral
2. Type
a. Inguinofemoral
b. Ilio-inguinal
Reconstruction with Flap
1. Flap used
2. Primary Closure without Flap
Post operative Histopathology:
1. Primary Lesion
2. Margin Status
a. Free
b. Close Margin
c. Positive Margin
3. Nodal status
a. Positive
b. Positive with Extracapsular Spread
c. Negative
4. Nodal Yield
a. Total number of nodes
b. Positive Nodes
FIGO Stage (2009):
Postoperative complications:
1. Seroma
2. Wound Infection
3. Wound Dehiscence due to necrosis
4. Others
Adjuvant Therapy:
1. EBRT
2. Chemotherapy
3. Chemo-RT
Recurrence Pattern:
1. Site
a. Local
b. Regional
c. Systemic
2. Time Taken
3. Salvage of Recurrence
a. Surgery
b. EBRT
c. Chemo-RT
Follow-up details:
1. Disease Free Period
2. Total Follow-up Period
3. Current Status
a. Alive
i. With Disease
ii. Without Disease
b. Dead
c. Defaulted Follow-up
S.No Name Age CD no Itching Ulcer Pain Others DM
Retroviral
status
Other
cutaneous
Lesion
Previous
Malignancy
Family H/O
malignancy
Predominant Side
of involvement Site Size
Node
involvement
Clinically Urethra Anus Vagina Previous treatment
Pre operative
treatment DOS
1 Malliga Simon 40 296/04 yes yes yes discharge Nil Negative No No No Right Right Labia majora 3x3 cm Right inguinal Normal Normal No Nil Nil 1/4/2004
2 Anjalai 27 527/04 yes yes no no Nil Negative No No No Bilateral
Bilateral Labia majora
(multiple warty lesions)
multiple small
lesions,
largest 2x1 cm No Normal Normal No Nil Nil 13/05/2004
3 Rajalakshmi 30 539/04 yes yes no no Nil Negative No No No Bilateral Bilateral Labia majora 6x4 cm
Right inguinal 6x4
cm - fixed Normal Normal No Nil
50 GY EBRT 25
# 20/07/2004
4 Ethirajam 62 826/04 yes yes yes discharge Nil Negative No No
sister had Ca.
breast Bilateral
Bilateral,lower 1/3
vagina involved 6x3 cm Right inguinal
Yes
lower1/3 Normal
yes
lower1/3
Excision elsewhere 2
years back
40 GY EBRT 20
# 1/11/2004
5 Jothimani 45 607/05 yes yes no no Nil Negative No No No Right Right Labia majora 3x2 cm No Normal Normal No Nil nil  17/06/05
6 Lakshmiammal 60 704/05 yes yes no no Nil Negative No No No Right Right Labia majora 4X3 cm No Normal Normal No Nil nil 22/06/2005
7 Sundarammal 50 840/05 no yes no no Nil Negative No No No Bilateral Bilateral labia majora 5x5 cm No Normal Normal No Nil Nil 5/8/2005
8 Mangammal 65 141/06 no yes no no Nil Negative No No No Right
Right Labia minora with
Clitoris 2x2 cm No Normal Normal No Nil Nil 16/02/2006
9 Jayalakshmi 60 292/06 yes yes no no Nil Negative No No
Maternal Uncle
& Elder Brother
had Ca.
Esophagus Right
Rt Labia majora, Rt
labia minora, close to
anus 4x3 cm Right Inguinal Normal Normal No Topical Ointments nil 10/4/2006
10 Annammal 60 914/06 no yes yes no Nil Negative No No No Right Right Labia minora 1.5x1 cm No Normal Normal No Punch Biopsy Elsewhere nil 26/08/2006
11 Tamilarasi 35 1026/06 yes yes yes no Nil Negative No No No Right
Rt labia majora
involving rt labia minora
and clitoris 6x4cm No Normal Normal No Nil nil 9/9/2006
12 Abaranji 65 1032/06 yes yes no no yes Negative No No
Son had Ca.
Stomach Bilateral
labia majora,minora
onboth sides, clitoris 6X4 cm No Normal Normal No Punch Biopsy Elsewhere nil 16/09/06
13 Samiammal 55 1426/06 yes yes yes no Nil Negative Leukoderma No No Left  Labia minora - Left 5x3 No Normal Normal No Topical Ointments nil 8/12/2006
14 Chinnammal 55 555/07 no yes no no Nil Negative No Ca.cervix IIIB No Right Right labia majora 4x3 cm No Normal Normal No
known Ca. cervix IIIB
treated with Radical RT
4 years back nil 15/05/2007
15 Tamilarasi Gopalan48 1506/07 yes yes no no Nil Negative No No No Left
Left labia majora with
distal1/3 vagina 5x3 cm Left inguinal Normal Normal lower 1/3 Nil Nil 24/11/2007
16 Gowrammal 59 1531/07 no yes yes discharge Nil Negative No No No Right
Rightlabia majora and
labia minora extending
to perineal body 6x4 cm Right inguinal Normal Normal No Nil 50 GY EBRT 8/12/2007
17 Pappammal 50 61/08 yes yes yes no Nil Negative No No No Bilateral Both Labia majora 4x3 cm Bilateral inguinal Normal Normal No Nil Nil 5/2/2008
18 Ruckmani 54 218/08 yes yes no no Nil Negative No No No Right
Right Labia majora
involving urethral
meatus 4x3 cm Bilateral inguinal
yes
meatus Normal No
Splenectomy for
Autoimmune Hemolytic
Anemia 3 years back Nil 19/02/2008
19 Vediammal 42 1060/08 no yes no no Nil Positive No No No Right Right Labia majora 2x3cm No Normal Normal No Nil Nil 5/7/2008
20 Savithri 61 1145/08 no yes no bleeding Nil Negative No No No Right
Right labia majora
involving clitoris 3x2 cm Left inguinal Normal Normal No Nil Nil 24/07/2008
21 Kaladevi 45 1217/08 yes yes yes discharge Nil Negative No No No Bilateral
Bilateral labia majora
with clitoris 6x3 cm No Normal Normal No Nil Nil 25/07/2008
22 Muniammal Devakumar65 1885/08 yes yes no no Nil Negative No No
Daughter had
Ca. cervix Right
Entire Right vulva
extending to left side 5x3 cm Bilateral inguinal
yes
meatus Normal No Nil Nil 10/12/2008
23 Vimala 50 1922/08 yes yes no no Nil Negative No No No Left Left Labia majora 1x1 cm Left inguinal Normal Normal No
40 GYEBRT elsewhere ,
2months before
admission Nil 19/12/2008
24 Mary 58 14/09 yes yes no no Nil Negative No No No Right Right labia majora 5x4cm No Normal Normal No Nil Nil 27/01/2009
25 Gangammal 65 364/09 yes yes no no Yes Negative No No No Right Right labia minora 3x2 cm No Normal Normal No Nil Nil 21/04/2009
26 Jayammal 60 850/09 yes yes no no Nil Negative No No No Bilateral
Bilateral labia majora
anteriorly 4x3 cm No Normal Normal No Nil nil 22/07/2009
27 Anila 23 956/09 no yes no no Nil Negative No No No Right
Entire right hemivulva
upper half of left
hemivulva,distal urethra 6x3 cm No
Distal
urethra Normal No Nil
Concurrent
chemo RT, (50
GY 25 #, 3
cycles of PF
chemo) 5/11/2009
28 Velankanni 45 163/10 yes no no no Nil Negative No No No Right Right labia minora 2x2 cm No Normal Normal No
Vaginal Hysterectomy 4
months back Nil 15/03/2010
29 Thenammal 50 454/10 no yes no no Nil Negative No No No Clitoris Clitoris 2x1cm No Normal Normal No
Excision biopsy
elsewhere nil 26/05/2010
30 Thamayanthi 65 503/10 yes no no swelling Nil Negative No No No Right Right labia majora 2x1 cm No Normal Normal No
Excision biopsy
elsewhere, vaginal
hysterectomy 5 years
back nil 20/05/2010
31 Nirmala 55 783/10 yes no no no Nil Negative No No No Left
Left labia majora with
Clitoris 3x2 cm No Normal Normal No Topical Ointments Nil 10/8/2010
32 Therasammal 73 891/10 yes yes no no Nil Negative leucoderma No No Right Right labia majora 3x4cm No Normal Normal No Nil Nil 19/08/2010
33 Alagammal 50 471/11 yes yes no no yes Negative No No No Clitoris Clitoris 3x2 cm No Normal Normal No Nil nil 7/5/2011
34 Syriapuspam 60 806/11 yes yes no no yes Negative No No No Right Right labia majora 3x4cm No Normal Normal No Nil Nil 9/8/2011
35 Rathinam 50 1012/11 yes yes no no yes Negative No No No Right
Right labia majora with
clitoris 5x3 cm No Normal Normal No Nil Nil 19/09/2011
Surgery Nodal dissection Flap Reconstruction
Post operative
complication
Post Operative
HPE
Margin
status Nodal status
No of
nodes
positive
Nodal
positivity
Nodal
positivity
with ECS
FIGO
stage Adjuvant RT
Adjuvant
Chemoth
erapy
Pattern of
recurrence
Treatment of
recurrence
DFS in
months
Total follow up
period in
months Status
Wide Local Excision
Right Ilioinguinal Block
Dissection Nil Skin flap necrosis SCC Free
 Right inguinal  5/8 +,
Right pelvic  7/7 free 5 out of 15 Positive
Positive
without
ECS III Defaulted RT Nil Nil Nil 36 36
Alive & defaulted
followup
Simple vulvectomy Nil Nil Uneventful SCC Gr-I Free Nil NA NA NA I Nil Nil
Right inguinal node
5 months after
primary surgery
Right Ilioinguinal Block
Disection with Extended
TFL flap Rt inguinal
regionon 05/11/2004, HPE-
Right inguinal 7/10 +ve,
Right pelvic 1/6  +ve, 50GY
EBRT 25 # as adjuvant 5 26
Alive  & defaulted
follow up
Radical Vulvectomy
Right Ilioinguinal, Left
inguinofemoral Block
Dissection
TFL flap Rt inguinal
region Uneventful
SCC-
nonkeratinizing
Gr- II Free
Right inguinal 14/14 free,
Left inguinal 11/11 free,
Right pelvic 7/7 free 0 out of 32 Negative Negative IVA Nil Nil Nil Nil 56 56 Alive
Radical Vulvectomy
Rt ilioinguinal, Lt
inguinofemoral Block
Dissection
Bilateral Gracilis
myocutaneous flap for
primary surgery, TFL
flap for Rt inguinal
region
Gracilis flap
necrosis,on 07/11/2004
Diversion colostomy
with removalof
necrosed flaps SCC Gr-II
posterior
margin +ve
Rt inguinal 12/12 + with
perinodal disease, Lt
inguinal 1/5 +ve, Rt pelvic
nodes 6/7 +ve with
perinodal disease
19 out of
24 Positive
Positive
with ECS IVB Nil Nil Nil Nil 20 20 Dead
Radical Vulvectomy
Right ilioinguinal Block
Dissection Nil Skin flap necrosis SCC- Gr-I Free
Right inguinal 1/8 +, Right
iliac 4/4 free 1out of 12 Positive
Positive
without
ECS III Nil Nil
Left inguinal nodes
matted on
06/10/2005
50 GY
EBRT,nonresponsive 16
GY EBRT, 1cycle chemo
CDDP, 5FU,patient
defaulted 4 14 Dead
Simple Vulvectomy Nil Nil Uneventful SCC Gr-I Free Nil NA NA NA I Nil Nil Nil Nil 60 60 Alive
Radical Vulvectomy
Bilateral Inguinofemoral Block
Dissection Nil Skin flap necrosis SCC Gr-II Free
Right inguinal 2/8 +,Left
inguinal 7/7 free 2 out of 15 Positive
Positive
without
ECS III
50GY  EBRT
25 # Nil Nil Nil 58 58 Alive
Right
Hemivulvectomy
Right Inguinofemoral Block
Dissection Nil
Wound infection with
skin flap necrosis
SCC- small cell
keratinizing
1/4th margin
+ve Right inguinal  6/6 free 0 out of 6 Negative Negative I
Defaulted RT
(came after 15
months) Nil Nil Nil 67 67 Alive
Radical Vulvectomy
Right Inguinofemoral Block
Dissection Nil Skin flap necrosis SCC- Gr-I Free Right inguinal  9/9 free 0 out of 9 Negative Negative I Nil Nil Nil Nil 54 54 Alive
Wide Local Excision Nil Nil Uneventful SCC- Gr-I Free Nil NA NA NA I Nil Nil Nil Nil 61 61 Alive
Radical Vulvectomy
Bilateral Inguinofemoral Block
Dissection Nil Uneventful SCC- Gr-I Free
Right inguinal  7/7 free,
Left inguinal  8/8 free 0 out of 15 Negative Negative I Nil Nil Nil Nil 48 48 Alive
Radical Vulvectomy
Bilateral Inguinofemoral Block
Dissection Nil Skin flap necrosis
Verrucous
Carcinoma,
areas of invasion
2 mm Free
Right inguinal  9/9 free,
Left  inguinal 5/5 free 0 out of 14 Negative Negative I Nil Nil Nil Nil 61 61 Alive
Radical Vulvectomy
Bilateral Inguinofemoral Block
Dissection Nil Skin flap necrosis SCC- Gr-I
Free,Urethra
Free
Right inguinal  4/5 +,Left
inguinal  7/11 +
11 out of
16 Positive
Positive
without
ECS III Defaulted RT Nil Nil Nil 41 41
Alive & defaulted
followup
Radical Vulvectomy
Bilateral Inguinofemoral Block
Dissection Nil Skin flap necrosis
SCC-
Nonkeratinizing Free
Right inguinal 7/7 free,
Left inguinal 9/9 free 0 out of 16 Negative Negative I Nil Nil
local recurrence
04/02/2010 (33
months after
surgery)
brachytherapy planned, pt
defaulted 33 46 Alive with Disease
Radical Vulvectomy
Left Inguinofemoral Block
Dissection TFL flap left side
Distal part of TFL flap
necrosis, DVT Lt Iliac
veins & CFV & PV
SCC large cell
type Free Left inguinal 1/10 + 1 out of 10 Positive
Positive
without
ECS III
60 Gy EBRT
30 # Nil periurethral region Defaulted followup 31 43 Alive with Disease
Radical Vulvectomy
Bilateral Ilioinguinal Block
Dissection TFL flap rt side
perineal wound
infection treared
SCC-
keratinizing
Right lateral
margin close
Right inguinal 3/7 +, Right
iliac 4/4 free, Left inguinal
6/6 free,Left iliac 4/4 free 3 out of 21 Positive
Positive
without
ECS III Nil Nil Nil Nil 25 25 Alive
Radical Vulvectomy
Bilateral Inguinofemoral Block
Dissection Nil Uneventful
SCC keratinizing
large cell type Free
Right inguinal 10/10 free,
Left inguinal 2/9 +ve with
perinodal disease 2 out of 19 Positive
Positive
with ECS IIIC Defaulted  RT Nil
Ulcer Left inguinal
region 6 months
after primary
surgery 60 GY EBRT 6 10 Dead
Radical Vulvectomy
Bilateral inguinofemoral Block
Dissection Nil
Skin flap necrosis,
slough excision, SSG SCC keratinizing Free
Right inguinal 3/10 +ve
with perinodal disease,
Left inguinal 4/4 free 3 out of 14 Positive
Positive
with ECS IIIC
50GY  EBRT
25 # Nil
local recurrence 30-
11-09 ( 21 months
after primary
surgery)
Chemotherapy received -
PF 1 cycle 21 25 Dead
Wide Local Excision Nil Nil Uneventful
SCC ,3mm
invasion Free Nil NA NA NA I Defaulted RT Nil Nil Nil 39 39 Alive
Radical Vulvectomy
Bilateral inguinofemoral Block
Dissection Nil Uneventful SCC keratinizing Free
Right inguinal 13/13 free,
Left inguinal 8/8 free 0 out of 21 Negative Negative I Nil Nil Nil Nil 26 26 Alive
Radical Vulvectomy
Bilateral Inguinofemoral Block
Dissection Nil Uneventful
Basisquamous
cell carcinoma Free
Right inguinal 13/13 free,
Left inguinal 6/6 free 0 out of 19 Negative Negative I Nil Nil
Clinical nodal
recurrence at 13
months ,no biopsy
proof Defaulted followup 13 13
Alive & defaulted
followup
Radical Vulvectomy
Bilateral inguinofemoral Block
Dissection Nil Skin flap necrosis
SCC Gr-I,
minimally
invasive Free
Right inguinal 7/7 free,
left inguinal 6/6  free 0 out of 13 Negative Negative II Nil Nil Nil Nil 33 33 Alive
Radical Vulvectomy
Bilateral Inguinofemoral Block
Dissection
TFL flap Lt inguinal
region
Skin flap necrosis rt
side, marginal wound
gap lt side
No residual
tumor Free
Right inguinal 13/13 free,
Left inguinal 2/13 +ve 2 out of 26 Positive
Positive
without
ECS III Nil Nil Nil Nil 19 19 Alive
Radical Vulvectomy
Bilateral Inguinofemoral Block
Dissection Nil Uneventful SCC- Gr-II Free
Right inguinal node 7/7
free, Left inguinal 2/8 +ve
with perinodal disease 2 out of 15 Positive
Positive
with ECS IIIC
50GY  EBRT
25 # Nil Nil Nil 14 14
Alive & defaulted
followup
Radical Vulvectomy
Bilateral Inguinofemoral Block
Dissection Nil Skin flap necrosis SCC- Gr- I Free
Right inguinal 9/9 free,
Left inguinal 11/11 free 0 out of 20 Negative Negative I Nil Nil Nil Nil 29 29 Alive
Radical Vulvectomy
Bilateral Inguinofemoral Block
Dissection Nil Uneventful SCC Gr-I Free
Right inguinal 2/9 +, Left
inguinal 3/11 + 5 out of 20 Positive
Positive
without
ECS III
60 Gy EBRT
30 # Nil Nil Nil 27 27 Alive
Radical Vulvectomy
Bilateral Inguinofemoral Block
Dissection Nil Uneventful
Tiny residual
SCC Free
Right inguinal 3/3 free,
Left inguinal 3/3 free 0 out of 6 Negative Negative II Nil
3cycles of
PF
Multiple metastases
lung,humerus
4 cycles of chemo with PF,
20 GY RT 5# for deposit
humerus medial condyle on
January 2011 8 21 Alive with Disease
Right
Hemivulvectomy
Right Inguinofemoral Block
Dissection Nil Uneventful SCC Gr-II Free Right inguinal 8/8 free 0 out of 8 Negative Negative I Nil Nil
soft tissue
recurrence in rt
inguinal region on
22-06-10,FNAC +
(Chemo-RT) 50Gy EBRT
with 6 cycles of chemo with
PF- completed on 12-03-11 3 20 Alive
Radical Vulvectomy
Bilateral Inguinofemoral Block
Dissection Nil Uneventful
No residual
tumor Free
Right inguinal 8/8 free,
Left inguinal 7/7 free 0 out of 15 Negative Negative I Nil Nil Nil Nil 18 18 Alive
Radical Vulvectomy
Bilateral Inguinofemoral Block
Dissection Nil Uneventful
No residual
tumor Free
Right inguinal 5/5 free,
Left inguinal 5/5  free 0 out of 10 Negative Negative I Nil Nil Nil Nil 17 17 Alive
Radical Vulvectomy
Bilateral Inguinofemoral Block
Dissection Nil Uneventful SCC Gr-II Free
Right inguinal 2/11 +ve,
Left inguinal 10/10 free 2 out of 21 Positive
Positive
without
ECS III
50GY  EBRT
25 # Nil Nil Nil 15 15 Alive
Radical Vulvectomy
Bilateral inguinofemoral Block
Dissection Nil Skin flap necrosis SCC Gr-I Free
Right inguinal 11/11 free,
Left inguinal 6/6  free 0 out of 17 Negative Negative I Nil Nil Nil Nil 14 14 Alive
Radical Vulvectomy
Bilateral Inguinofemoral Block
Dissection Nil
Marginal skin flap
necrosis,secondary
suturing on 16-06-11 SCC-Gr-I Free
Right inguinal 8/8 free,
Left inguinal 9/9 free 0 out of 17 Negative Negative I Nil Nil Nil Nil 6 6 Alive
Radical Vulvectomy
Bilateral Inguinofemoral Block
Dissection Nil Uneventful SCC Gr-II Free
Right inguinal 2/10 +, Left
inguinal 5/14 + 7 out of 24 Positive
Positive
without
ECS III
50GY  EBRT
25 # Nil Nil Nil 3 3 Alive
Radical Vulvectomy
Bilateral Inguinofemoral Block
Dissection Nil Uneventful SCC Gr-I Free
Right inguinal 9/9 free,
Left inguinal 8/8 free 0 out of 17 Negative Negative I Nil` Nil Nil Nil 2 2 Alive
